Swedish personalised immunotherapy specialist Neogap Therapeutics AB has acquired the remaining shares of its subsidiary, TCER Oncology AB through two new shareholders.

An international research team headed by Pablo Guardado-Calvo at Institut Pasteur Paris has demonstrated evaluated antibody efficacy against lethal hantaviruses.

The new Krakow headquarters of preclinical CRO Selvita have opened.

3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological drugs advances its international expansion with the opening of its first commercial office in the United States located in Boston, Massachusetts.

How to stop the silent pandemic AMR was discussed by 500 experts from 13 countries at the 7th AMR Conference in Basel. At that time, in Brussels, there were two proposals on the table on how to compensate novel resistance-breaking antimicrobials, from which one got the green light in the new pharma legislation.

Syncona Ltd had spun-out the ophtalmology specialist Beacon Therapeutics Holdings Ltd with a £96m Series A financing.

Roche AG has announced positive results from the non-blinded Phase III COMMODORE 1 and 2 trials at the EHA Hybrid Congress in Frankfurt, Germany.

The world 3rd largest gene and cell therapy (CGT) cluster, the UK CGT Catapult has expanded its operations opening a subsidiary in Edinburgh.

Leiden-based Amarna Therapeutics announces the appointment of Dr Henk Streefkerk as the company’s new Chief Executive Officer and Medical Director. Streefkerk has already been Amarna’s Medical Director since mid-2022.

“At the IZB, we are right in the middle of it all—as one of the leading cell culture specialists in the heart of Germany’s biotech hotspot and as a medium manufacturer in life science research.”